Pages that link to "Q43613003"

The following pages link to A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors (Q43613003):

Displayed 50 items.

• Human immunodeficiency virus & cardiovascular risk (Q22241184) ‎ (← links)
• The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications (Q24598812) ‎ (← links)
• Adverse effects of antiretroviral therapy for HIV infection (Q24617882) ‎ (← links)
• An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome (Q24791238) ‎ (← links)
• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS (Q24792952) ‎ (← links)
• High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus (Q24814179) ‎ (← links)
• Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report (Q24814430) ‎ (← links)
• Antiretroviral therapy and dyslipidaemia: unlocking the code (Q25256933) ‎ (← links)
• Metabolic syndrome, diabetes, and cardiovascular risk in HIV (Q26853470) ‎ (← links)
• The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism (Q27021950) ‎ (← links)
• A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization (Q27498795) ‎ (← links)
• The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology (Q27932399) ‎ (← links)
• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review (Q28220294) ‎ (← links)
• Clinical review#: Lipodystrophies: genetic and acquired body fat disorders (Q28246346) ‎ (← links)
• Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype (Q28344599) ‎ (← links)
• Metabolic effects of indinavir in healthy HIV-seronegative men (Q28366603) ‎ (← links)
• Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir (Q28372555) ‎ (← links)
• Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases (Q28378450) ‎ (← links)
• Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening (Q28485115) ‎ (← links)
• Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study (Q28543075) ‎ (← links)
• HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus (Q28582686) ‎ (← links)
• Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine (Q28743352) ‎ (← links)
• Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study (Q28744647) ‎ (← links)
• Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques (Q28775900) ‎ (← links)
• Side effects of HIV therapy (Q29394405) ‎ (← links)
• Novel functions of PXR in cardiometabolic disease (Q30251861) ‎ (← links)
• Ongoing trials in HIV protease inhibitors. (Q30327423) ‎ (← links)
• Managing the care of patients infected with bloodborne diseases (Q30332745) ‎ (← links)
• 'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. (Q30385053) ‎ (← links)
• Getting to 90-90-90 in paediatric HIV: What is needed? (Q30385352) ‎ (← links)
• Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients (Q30480466) ‎ (← links)
• Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. (Q30762470) ‎ (← links)
• The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database (Q30771406) ‎ (← links)
• Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data (Q30795793) ‎ (← links)
• Identification of allosteric peptide agonists of CXCR4. (Q30868390) ‎ (← links)
• iMPACT3: Internet-based development and administration of utility elicitation protocols (Q30872297) ‎ (← links)
• Use of observational data in evaluating treatments: antiretroviral therapy and HIV. (Q30969932) ‎ (← links)
• Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors (Q31055878) ‎ (← links)
• Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. (Q31143771) ‎ (← links)
• The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy (Q32058552) ‎ (← links)
• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children (Q33378805) ‎ (← links)
• Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study (Q33389734) ‎ (← links)
• Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). (Q33404972) ‎ (← links)
• The use of combination antiretroviral therapy in HIV-infected patients (Q33543115) ‎ (← links)
• The association of HIV infection with left ventricular mass/hypertrophy (Q33570964) ‎ (← links)
• HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications (Q33604216) ‎ (← links)
• A risk-benefit assessment of HIV protease inhibitors (Q33609283) ‎ (← links)
• Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. (Q33640982) ‎ (← links)
• Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults (Q33691689) ‎ (← links)
• Inpatient health services utilization among HIV-infected adult patients in care 2002-2007. (Q33699011) ‎ (← links)